Efficacy and safety of DSA-guided percutaneous sclerotherapy for venous malformations of penile region in children
jpedsurg.org shows its articles on its own site.
Read the article on jpedsurg.org ↗Article · Aug 2020 · 1 min read
In brief
In brief
Case series of 9 pediatric patients with penile venous malformations treated with DSA-guided percutaneous sclerotherapy using pingyangmycin and polidocanol. After average 2.3 treatment sessions, 6 patients achieved cure and 3 achieved basic remission with minimal complications and preserved penile function.
Written by the GCMD Library team from the article.
Abstract
Objective
To describe the effectiveness and security of DSA-guided percutaneous sclerotherapy for venous malformations of penile region in children.
Methods
A total of 9 cases children with penile venous malformations treated by DSA-guided percutaneous sclerotherapy from January 2017 to June 2018 were enrolled in this study. Local angiography was performed under DSA fluoroscopy, and the shape, extent and venous drainage of the tumor nest were judged. Then sclerosing agents (Pingyangmycin and Polidocanol) were selected according to the flow rate of angiography and treated by percutaneous injection under DSA monitoring. Imaging examination (MRI) was performed to evaluate clinical improvement.
Results
A total of 26 interventional sclerotherapy sessions were performed in 9 children, with an average of (2.3±0.5) sessions per case. After a mean follow-up of 7.3 months, 6 cases were cured, and 3 cases were in basic remission. There were 9 cases of temporary edema secondary to the treatment site and 3 cases of mild pain. No serious complications such as ulceration, hemorrhage, infection and dysfunction occurred in any patients.
Conclusion
DSA-guided percutaneous sclerotherapy for venous malformations of penile region in children is safe and effective, does not affect the appearance and function of penis, and is worthy of clinical promotion.
Type of study
Treatment Study.
Level of evidence
Level IV, Case series with no comparison group.